Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Construction and Validation of a Nomogram for Predicting Progression- Free Survival in Patients with Early-Stage Testicular Germ Cell Tumor

Author(s): Jin-Guo Chen, Jing-Quan Wang, Tian-Wen Peng, Zhe-Sheng Chen* and Shan-Chao Zhao*

Volume 16, Issue 1, 2021

Published on: 11 February, 2021

Page: [44 - 53] Pages: 10

DOI: 10.2174/1574892816666210211092108

Price: $65

Open Access Journals Promotions 2
conference banner
Abstract

Background: Testicular Germ Cell Tumor (TGCT) is the most common malignant tumor in young men, but there is a lack of a prediction model to evaluate the prognosis of patients with TGCT.

Objective: To explore the prognostic factors for Progression-Free Survival (PFS) and construct a nomogram model for patients with early-stage TGCT after radical orchiectomy.

Methods: Patients with TGCT from The Cancer Genome Atlas (TCGA) database were used as the training cohort; univariate and multivariate cox analysis was performed. A nomogram was constructed based on the independent prognostic factors. Patients from the Nanfang Hospital affiliated with Southern Medical University were used as the cohort to validate the predictive ability using the nomogram model. Harrell's concordance index (C-index) and calibration plots were used to evaluate the nomogram.

Results: A total of 110 and 62 patients with TGCT were included in the training cohort and validation cohort, respectively. Lymphatic Vascular Invasion (LVI), American Joint Committee on Cancer (AJCC) stage and adjuvant therapy were independent prognostic factors in multivariate regression analyses and were included to establish a nomogram. The C-index in the training cohort for 1- , 3-, and 5-year PFS were 0.768, 0.74, and 0.689, respectively. While the C-index for 1-, 3-, and 5- year PFS in the external validation cohort were 0.853, 0.663 and 0.609, respectively. The calibration plots for 1-, 3-, and 5-year PFS in the training and validation cohort showed satisfactory consistency between predicted and actual outcomes. The nomogram revealed a better predictive ability for PFS than AJCC staging system.

Conclusion: The nomogram as a simple and visual tool to predict individual PFS in patients with TGCT could guide clinicians and clinical pharmacists in therapeutic strategy.

Keywords: Testicular cancer, testicular germ cell tumor, platinum-based chemotherapy, nomogram, progression-free survival, recurrence, prognosis.

« Previous Next »
[1]
La Vecchia C, Bosetti C, Lucchini F, et al. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 2010; 21(6): 1323-60.
[http://dx.doi.org/10.1093/annonc/mdp530] [PMID: 19948741]
[2]
Baird DC, Meyers GJ, Hu JS. Testicular cancer: Diagnosis and treatment. Am Fam Physician 2018; 97(4): 261-8.
[PMID: 29671528]
[3]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69(1): 7-34.
[http://dx.doi.org/10.3322/caac.21551] [PMID: 30620402]
[4]
Ghazarian AA, Kelly SP, Altekruse SF, Rosenberg PS, McGlynn KA. Future of testicular germ cell tumor incidence in the United States: Forecast through 2026. Cancer 2017; 123(12): 2320-8.
[http://dx.doi.org/10.1002/cncr.30597] [PMID: 28241106]
[5]
Cai Q, Chen Y, Zhang D, et al. Estimates of over-time trends in incidence and mortality of testicular cancer from 1990 to 2030. Transl Androl Urol 2020; 9(2): 182-95.
[http://dx.doi.org/10.21037/tau.2020.02.22] [PMID: 32420124]
[6]
Heidenreich A, Knüchel-Clarke R, Pfister D. Importance of pathology for therapy planning of testicular germ cell tumors. Pathologe 2014; 35(3): 266-73.
[http://dx.doi.org/10.1007/s00292-014-1903-5] [PMID: 24771259]
[7]
Pollard JR, Reaper PM. Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors. WO2013049859, 2013.
[8]
Mcclay EF, Howell SB. Combination cisplatin/tamoxifen therapy for human cancers. WO1994018990, 1994.
[9]
Hugh G. Combination therapy for cancer. US20200268783, 2020.
[10]
Hanna N, Einhorn LH. Testicular cancer: A reflection on 50 years of discovery. J Clin Oncol 2014; 32(28): 3085-92.
[http://dx.doi.org/10.1200/JCO.2014.56.0896] [PMID: 25024068]
[11]
Chovanec M, Hanna N, Cary KC, Einhorn L, Albany C. Management of stage I testicular germ cell tumours. Nat Rev Urol 2016; 13(11): 663-73.
[http://dx.doi.org/10.1038/nrurol.2016.164] [PMID: 27618772]
[12]
Pompe RS, Bandini M, Preisser F, et al. Contemporary approach to predict early biochemical recurrence after radical prostatectomy: Update of the Walz nomogram. Prostate Cancer Prostatic Dis 2018; 21(3): 386-93.
[http://dx.doi.org/10.1038/s41391-018-0033-1] [PMID: 29487397]
[13]
Walz J, Chun FK, Klein EA, et al. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol 2009; 181(2): 601-7.
[14]
Cambier S, Sylvester RJ, Collette L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage ta-t1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Guérin. Eur Urol 2016; 69(1): 60-9.
[http://dx.doi.org/10.1016/j.eururo.2015.06.045] [PMID: 26210894]
[15]
Kollmannsberger C, Tandstad T, Bedard PL, et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol 2015; 33(1): 51-7.
[http://dx.doi.org/10.1200/JCO.2014.56.2116] [PMID: 25135991]
[16]
Gels ME, Hoekstra HJ, Sleijfer DT, et al. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: A single-center 10-year experience. J Clin Oncol 1995; 13(5): 1188-94.
[http://dx.doi.org/10.1200/JCO.1995.13.5.1188] [PMID: 7537802]
[17]
Li X, Guo S, Wu Z, et al. Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors. World J Urol 2015; 33(9): 1351-7.
[http://dx.doi.org/10.1007/s00345-014-1454-7] [PMID: 25471669]
[18]
Blok JM, Pluim I, Daugaard G, et al. Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: A systematic review and meta-analysis. BJU Int 2020; 125(3): 355-68.
[http://dx.doi.org/10.1111/bju.14967] [PMID: 31797520]
[19]
Ahmed KA, Wilder RB. Outcomes and treatment patterns as a function of time in stage IS testicular seminoma: A population-based analysis. Cancer Epidemiol 2014; 38(2): 124-8.
[http://dx.doi.org/10.1016/j.canep.2014.02.003] [PMID: 24613492]
[20]
Lv ZJ, Wu S, Dong P, et al. Clinical outcomes in patients with stage I non-seminomatous germ cell cancer. Asian J Androl 2013; 15(4): 558-63.
[http://dx.doi.org/10.1038/aja.2013.16] [PMID: 23685909]
[21]
Escudero-Ávila R, Rodríguez-Castaño JD, Osman I, et al. Active surveillance as a successful management strategy for patients with clinical stage I germ cell testicular cancer. Clin Transl Oncol 2019; 21(6): 796-804.
[http://dx.doi.org/10.1007/s12094-018-1990-5] [PMID: 30470992]
[22]
Hosni A, Warde P, Jewett M, et al. Clinical characteristics and outcomes of late relapse in stage I testicular seminoma. Clin Oncol (R Coll Radiol) 2016; 28(10): 648-54.
[http://dx.doi.org/10.1016/j.clon.2016.06.001] [PMID: 27339401]
[23]
Tandstad T, Dahl O, Cohn-Cedermark G, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: The SWENOTECA management program. J Clin Oncol 2009; 27(13): 2122-8.
[http://dx.doi.org/10.1200/JCO.2008.18.8953] [PMID: 19307506]
[24]
Singhera M, Lees K, Huddart R, Horwich A. Minimizing toxicity in early-stage testicular cancer treatment. Expert Rev Anticancer Ther 2012; 12(2): 185-93.
[http://dx.doi.org/10.1586/era.11.212] [PMID: 22316366]
[25]
Diamond J, Glasky AJ. Methods for treatment of drug-induced peripheral neuropathy and related conditions. WO2002004448, 2002.
[26]
van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007; 25(28): 4370-8.
[http://dx.doi.org/10.1200/JCO.2006.10.5296] [PMID: 17906202]
[27]
Glendenning JL, Barbachano Y, Norman AR, Dearnaley DP, Horwich A, Huddart RA. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 2010; 116(10): 2322-31.
[http://dx.doi.org/10.1002/cncr.24981] [PMID: 20225230]
[28]
Li Z, Zhou J, Gan Y, et al. Synthesis of a novel platinum(II) complex with 6,7-dichloro-5,8-quinolinedione and the study of its antitumor mechanism in testicular seminoma. J Inorg Biochem 2019; 197: 110701.
[http://dx.doi.org/10.1016/j.jinorgbio.2019.110701] [PMID: 31055215]
[29]
Lollo G, Benoit J-P, Brachet BM. Drug delivery system for platinum-based drugs. WO2020053445, 2020.
[30]
Kobayashi K, Saito T, Kitamura Y, et al. Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: Pathological risk factors for relapse and feasibility of surveillance after orchiectomy. Diagn Pathol 2013; 8: 57.
[http://dx.doi.org/10.1186/1746-1596-8-57] [PMID: 23566361]
[31]
Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD statement. Ann Intern Med 2015; 162(1): 55-63.
[http://dx.doi.org/10.7326/M14-0697] [PMID: 25560714]
[32]
Huang Y, Sheng H, Zhang J, Liu Q, Ye D, Shi G. Incorporating non-biological factors into the TNM staging system for better prognostication and decision-making in testicular cancer. World J Urol 2019; 37(10): 2165-73.
[http://dx.doi.org/10.1007/s00345-018-2603-1] [PMID: 30554272]
[33]
Anvar HAKI, Muhammad A. Bis-(triethylphosphine) platinum (II) complexes with thiones as anti-cancer agents. US09561237, 2017.
[34]
Shiladitya S, Monideepa R, Arindam S. Lipid-based platinum compounds and nanoparticles. US20190002489, 2019.
[35]
Dhar S, Pathak R, Marrache S. Mitochondria-targeting platinum (IV) prodrug. WO2015157409, 2015.
[36]
Chovanec M, Mardiak J, Mego M. Immune mechanisms and possible immune therapy in testicular germ cell tumours. Andrology 2019; 7(4): 479-86.
[http://dx.doi.org/10.1111/andr.12656] [PMID: 31169364]

Rights & Permissions Print Cite
Article Metrics
52
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy